Literature DB >> 17196841

Down-regulation of IGF-IR using small, interfering, hairpin RNA (siRNA) inhibits growth of human lung cancer cell line A549 in vitro and in nude mice.

Ai-Qiang Dong1, Min-Jian Kong, Zhi-Yuan Ma, Jian-Fang Qian, Xiao-Hong Xu.   

Abstract

Type I insulin-like growth factor receptor (IGF-IR), which is frequently overexpressed in a variety of human cancers including lung cancer, mediates cancer cell proliferation and tumor growth. In this study, we used a human U6 promoter-driven DNA-template approach to induce hairpin RNA (hpRNA)-triggered RNAi to silence IGF-IR gene expression in the human lung cancer cell line A549, and then evaluate its effects on apoptosis, apoptosis-related gene expression, and the growth of tumor cells in vitro and in nude mice. IGF-IR expression levels were found to markedly decrease in cells transfected with a plasmid expressing hairpin siRNA for IGF-IR (by more than 78.9%). Down-regulation of IGR-IR concomitantly accompanied reduction of bcl-2 as well as pERK and pAkt levels, activation of caspase-3, apoptosis and growth inhibition of A549 cells in vitro. Direct intratumoral injections of plasmid DNA expressing hpRNA for IGF-IR significantly regressed pre-established tumors in nude mice. Our results support the therapeutic potential of RNAi as a method for gene therapy in treating lung cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17196841     DOI: 10.1016/j.cellbi.2006.11.017

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  14 in total

1.  Down-regulation of IGF-1R expression inhibits growth and enhances chemosensitivity of endometrial carcinoma in vitro.

Authors:  Shanrong Shu; Yuebo Yang; Xiaomao Li; Tian Li; Yu Zhang; Chengfang Xu; Changyan Liang; Xiaoyun Wang
Journal:  Mol Cell Biochem       Date:  2011-03-26       Impact factor: 3.396

2.  GABAB receptor activation protects neurons from apoptosis via IGF-1 receptor transactivation.

Authors:  Haijun Tu; Chanjuan Xu; Wenhua Zhang; Qiuyao Liu; Philippe Rondard; Jean-Philippe Pin; Jianfeng Liu
Journal:  J Neurosci       Date:  2010-01-13       Impact factor: 6.167

Review 3.  The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer.

Authors:  Scott A Kono; Marianne E Marshall; Kathryn E Ware; Lynn E Heasley
Journal:  Drug Resist Updat       Date:  2009-06-04       Impact factor: 18.500

Review 4.  Post-transcriptional regulation of cytokine and growth factor signaling in cancer.

Authors:  Irina Vlasova-St Louis; Paul R Bohjanen
Journal:  Cytokine Growth Factor Rev       Date:  2016-12-02       Impact factor: 7.638

5.  Effects and mechanism of downregulation of survivin expression by RNA interference on proliferation and apoptosis of lung cancer cells.

Authors:  Xiang-Qi Chen; Sheng Yang; Zhi-Ying Li; Hui-Shan Lu; Ming-Qiang Kang; Ting-Yan Lin
Journal:  Mol Med Rep       Date:  2012-01-13       Impact factor: 2.952

6.  GABAB receptor subunit GB1 at the cell surface independently activates ERK1/2 through IGF-1R transactivation.

Authors:  Guillaume A Baloucoune; Lei Chun; Wenhua Zhang; Chanjuan Xu; Siluo Huang; Qian Sun; Yunyun Wang; Haijun Tu; Jianfeng Liu
Journal:  PLoS One       Date:  2012-06-28       Impact factor: 3.240

7.  Klotho inhibits growth and promotes apoptosis in human lung cancer cell line A549.

Authors:  Bo Chen; Xueli Wang; Weihong Zhao; Jianqing Wu
Journal:  J Exp Clin Cancer Res       Date:  2010-07-19

Review 8.  Development of small RNA delivery systems for lung cancer therapy.

Authors:  Yu Fujita; Kazuyoshi Kuwano; Takahiro Ochiya
Journal:  Int J Mol Sci       Date:  2015-03-06       Impact factor: 5.923

Review 9.  Vectors for inhaled gene therapy in lung cancer. Application for nano oncology and safety of bio nanotechnology.

Authors:  Paul Zarogouldis; Nikos K Karamanos; Konstantinos Porpodis; Kalliopi Domvri; Haidong Huang; Wolfgang Hohenforst-Schimdt; Eugene P Goldberg; Konstantinos Zarogoulidis
Journal:  Int J Mol Sci       Date:  2012-08-29       Impact factor: 6.208

10.  RNAi Therapeutic Platforms for Lung Diseases.

Authors:  Yu Fujita; Fumitaka Takeshita; Kazuyoshi Kuwano; Takahiro Ochiya
Journal:  Pharmaceuticals (Basel)       Date:  2013-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.